Skip to main content

Day: December 28, 2023

Carbide Inserts Market Size Worth USD 2.06 Billion in 2032 | Emergen Research

Rising demand for carbide inserts in industrial manufacturing is a key driving factor driving carbide inserts market revenue growth Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) — The global carbide inserts market size was USD 1.26 Billion in 2022 and is expected to register a rapid revenue CAGR of 5% during the forecast period. In the rapidly evolving landscape of industrial manufacturing, the global carbide inserts market is experiencing substantial growth, driven by the rising demand for carbide tools across various industries. Notably, aerospace, automobile, material handling, and construction sectors are leveraging carbide inserts to achieve high-precision metal shaping and grounding, leading to increased efficiency and profitability. One of the key factors contributing to the market’s revenue growth is the swift integration...

Continue reading

Natural Fragrance Market Size Worth USD 8.8 Million in 2032 | Emergen Research

Rising consumer demand regarding natural products is one of the major factors driving Natural Fragrance market revenue growth Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) — The global natural fragrance market size was USD 3.8 Million in 2022 and is expected to register a steady revenue CAGR of 8.8% during the forecast period, according to latest analysis by Emergen Research. Increasing social media promotions and advertisements is a key factor driving market revenue growth. Natural fragrance is derived from natural materials, such as plants and fruits, which has various applications, including perfumes, cosmetics, and food. These fragrances have healthy demand from consumers due to increasing awareness about the use of natural fragrances over synthetic fragrances and low toxicity of these compounds. For instance, on 18 August 2023,...

Continue reading

Butyl acetate Market Size Worth USD 1.86 Billion in 2032 | Emergen Research

Rising demand for butyl acetate in automotive coatings and refinishing applications, rapid expansion of the construction industry, and increasing adoption of butyl acetate in paints and coatings are key factors driving butyl acetate market revenue growth. Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) — The global Butyl acetate market size was USD 1.32 Billion in 2022 and is expected to register a rapid revenue CAGR of 3.4% during the forecast period. Key factors propelling this growth include the increasing demand for butyl acetate in automotive coatings, the expansion of the construction industry, and its adoption in paints and coatings. Key Market Drivers: Automotive and Construction Sectors Fuel Demand: Butyl acetate, also known as butyl ethanoate, is widely recognized for its versatility as a solvent in various applications, including...

Continue reading

Methyl acrylate Market Size Worth USD 674.9 Million in 2032 | Emergen Research

Rising adoption of methyl acrylate in adhesives and films, and rapid expansion of the construction and infrastructure sector across the globe are key factors driving Methyl acrylate market revenue growth. Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) — The global Methyl acrylate market size was USD 362.4 Million in 2022 and is expected to register a rapid revenue CAGR of 6.6% during the forecast period. Key drivers of this growth include the increasing demand for methyl acrylate in paints, coatings, adhesives, and films, along with the booming construction and infrastructure sector globally. Methyl acrylate, an organic compound derived from acrylic acid, has found widespread applications in high-tech industries such as paints and coatings, automotive, packaging, construction, and cosmetics. The rising popularity of the construction...

Continue reading

Bacterial Cellulose Market Size Worth USD 1,401.7 Million in 2032 | Emergen Research

Technological advancements in bacterial cellulose production and increasing need for bacterial cellulose in medical and healthcare industries are key factors driving Bacterial Cellulose Market revenue growth Vancouver, Dec. 28, 2023 (GLOBE NEWSWIRE) — The global bacterial cellulose market size was USD 426.7 Million in 2022 and is expected to register a rapid revenue CAGR of 12.6% during the forecast period. In recent years, the global bacterial cellulose market has experienced a significant surge, driven by advancements in molecular biology and fermentation techniques. This versatile material finds applications in various industries, ranging from medical to food products and beyond. Bacterial cellulose, a polysaccharide produced by certain bacterial species, boasts exceptional properties such as microporosity, high water-holding...

Continue reading

MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army

Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million YAVNE, Israel, Dec. 28, 2023 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Department of Defense (DoD), through the Medical Technology Enterprise Consortium (MTEC), has awarded MediWound an additional $6.7 million in non-dilutive funding to develop NexoBrid® as a non-surgical solution for field-care burn treatment for the U.S. Army (the “MTEC Research Project Award”). The $14.4 million project budget will advance the development and production of a new, temperature-stable formulation of NexoBrid, positioning it as the first-line non-surgical...

Continue reading

ECARX and smart Form Joint Venture to Drive Development of Intelligent Automotive Products

SHANGHAI, China, Dec. 28, 2023 (GLOBE NEWSWIRE) — ECARX Holdings Inc. (Nasdaq: ECX) (“ECARX”), a global mobility technology provider, today announced that pursuant to a shareholders’ agreement dated November 16, 2023, a joint venture has been established between ECARX and smart, the new-premium intelligent all-electric auto brand, through their respective subsidiaries. The joint venture, smart (Zhejiang) Software Technology Co., Ltd. (“smart Software Technology”), aims to drive the development of industry-leading intelligent experiences within smart vehicles. Through this new partnership, ECARX and smart will work together to drive technological advances, expand the research and development ecosystem through talent exchanges and joint innovation, and accelerate their global expansion efforts. ECARX and smart previously...

Continue reading

Paramount Gold Nevada Closes $15 Million Financing With Sprott Streaming

WINNEMUCCA, Nev., Dec. 28, 2023 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) announced today that it has closed the previously announced $15 million financing with Sprott Resource and Streaming Royalty Corp. (“Sprott Streaming”), through the issuance of a non-dilutive Secured Royalty Convertible Note (“RCN”). The proceeds of the financing will be used to fund the continued permitting of the proposed Grassy Mountain Gold Mine in eastern Oregon, for general corporate purposes and for the repayment of the company’s outstanding debt.  Paramount CEO, Rachel Goldman commented, “With the receipt of the Notice to Proceed from the State of Oregon, the Grassy permitting process has taken on greater certainty and this financing will allow us to fund our activities through to the receipt...

Continue reading

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference on Thursday, January 4, 2023, at 2:25 p.m. ET. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3....

Continue reading

CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation

PRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the pivotal U.S. and Canadian STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) randomized controlled trial. STAR-T is a double-blind, randomized, controlled, multi-center pivotal trial that investigated the ability of DrugSorb®-ATR to reduce perioperative bleeding in 140 enrolled patients on ticagrelor (Brilinta®, Brilique® – AstraZeneca) undergoing cardiothoracic...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.